⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11680924 | 0.82 | ALDH1A1 (0.53) | — | |
| SCHEMBL15065505 | 0.81 | — | — | |
| SCHEMBL8939152 | 0.80 | SLC1A3 (0.36) | — | |
| SCHEMBL27486209 | 0.79 | SLC1A3 (0.46) | — | |
| SCHEMBL28981412 | 0.74 | — | — | |
| SCHEMBL14803640 | 0.74 | — | — | |
| SCHEMBL13711834 | 0.74 | — | — | |
| SCHEMBL12879790 | 0.74 | — | — | |
| SCHEMBL407037 | 0.74 | — | — | |
| SCHEMBL112582 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641771-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | UCB PHARMA SA (BE) | 2008-10-15 | — | — | EP | disclosed |
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1648868-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | Celltech R & D Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| EP-1641771-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | Celltech R & D Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004113298-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113312-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| EP-1030836-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LTD (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-6187924-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TUMOR NECROSIS FACTOR-ALPHA-MEDIATED DISEASES | DARWIN DISCOVERY, LTD. (GB) | 2001-02-13 | — | — | US | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
| EP-1030836-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-08-30 | — | — | EP | disclosed |
| EP-0968182-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999024399-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
| WO-1998005635-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1998-02-12 | — | — | WO | disclosed |